A Phase 2 Single-Arm, Open-Label, Multi-Center Clinical Study Evaluating the Efficacy and Safety of Disitamab Vedotin for Injection (RC48-ADC) in Patients with HER2-Expressing Locally Advanced or Metastatic Urothelial Carcinoma
Details
Age
Adult
Type of Study
Treatment
Locations
Memorial Hospital Central
Memorial Hospital North
Principal Investigator
Rubens Chang
Study ID
Protocol Number: 21-4384
More information available at ClinicalTrials.gov: NCT04879329
Categories
Is this Study for You?
Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers